menu
    • menu
    [{"orgOrder":0,"company":"Kane Biotech","sponsor":"Best Buy Medical Canada","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Best Buy Medical Canada","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Best Buy Medical Canada"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"BioStem Technologies","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ BioStem Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ BioStem Technologies"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Qatar Datamation Systems","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Qatar Datamation Systems","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Qatar Datamation Systems"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Salud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Salud Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Salud Pharma"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"ProgenaCare Global","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Kane Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Kane Biotech"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"University of Maryland","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Enzyme","year":"2022","type":"Collaboration","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Kane Biotech \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ University of Maryland"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Marc Edwards","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2022","type":"Private Placement","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Marc Edwards","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ Marc Edwards"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Enzyme","year":"2024","type":"Funding","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ NRC IRAP","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ NRC IRAP"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Enzyme","year":"2022","type":"Funding","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ US Department of Defense"}]

    Find Clinical Drug Pipeline Developments & Deals by Kane Biotech

    Menu

    Kane Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DispersinB

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial

                            Details : DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG), for the treatment of mild to moderate cases of Acne Vulgaris.

                            Product Name : DispersinB

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 13, 2025

                            Lead Product(s) : DispersinB

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Best Buy Medical Canada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kane Announces Canadian Distribution Agreement with Best Buy Medical for Revyve

                            Details : The agreement aims for the distribution of revyve, an antimicrobial wound gel product line in infection management and wound healing.

                            Product Name : Revyve

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 11, 2025

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Best Buy Medical Canada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : BioStem Technologies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Kane Biotech Changes US Partner for Revyve™ Antimicrobial Wound Gel Distribution

                            Details : BioStem Technologies will acquire exclusive US distribution rights for revyve from ProgenaCare Global.

                            Product Name : Revyve

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 27, 2024

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : BioStem Technologies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel

                            Details : Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.

                            Product Name : Revyve

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 14, 2024

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DispersinB

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : NRC IRAP

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kane Biotech to Participate in a Multinational Corporate Collaboration Project

                            Details : The funding will be used to develop a proof-of concept for its DispersinB Wound Gel, antibiofilm enzyme-based gel for treating chronic wounds.

                            Product Name : DispersinB

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            October 03, 2024

                            Lead Product(s) : DispersinB

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : NRC IRAP

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Qatar Datamation Systems

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kane Biotech Signs Deal with Qatar Datamation For Wound Gel Distribution

                            Details : The agreement aims for the distribution of revyve antimicrobial wound gel indicated for diabetic foot ulcers, in the Qatar wound care market.

                            Product Name : Revyve

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 28, 2024

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Qatar Datamation Systems

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : NRC IRAP

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kane Biotech Receives Funding Support to Expand the Revyve Antimicrobial Wound Gel Family

                            Details : The funding will support the development of three additional products to build on Kane Biotech’s revyve Antimicrobial Wound Gel technology for management of ulcers.

                            Product Name : Revye

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 13, 2024

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : NRC IRAP

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kane Biotech Receives FDA Approval to Increase Dosage of Revyve™ Wound Gel

                            Details : Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.

                            Product Name : Revye

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 23, 2024

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kane Biotech and ProgenaCare Global Launch Newly Rebranded Revyve™ Antimicrobial Wound Gel at Advanced Wound...

                            Details : revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult po...

                            Product Name : Revye

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 02, 2023

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel

                            Details : coactiv+ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult pop...

                            Product Name : coactiv+

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 25, 2023

                            Lead Product(s) : Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth